Adaptimmune Therapeutics (ADAP) Guggenheim SMID Cap Biotech Conference summary

Product innovation and clinical impact

• Achieved first-ever approval for a TCR T-cell therapy in solid tumors with TECELRA, targeting synovial sarcoma.

• TECELRA shows a 43% response rate, with deep and durable responses; 40% last over a year.

• Therapy addresses a significant unmet need, being the first new treatment in over a decade for synovial sarcoma.

• All pipeline products are autologous cell therapies, engineered for solid tumor recognition.

Commercial launch and site activation

• Treated first patient within projected timeline, with 11 treatment centers opened in 2023, exceeding expectations.

• Plan to have full network of 30 centers operational by end of 2024, accelerating from previous 2026 target.

• Early demand is strong, with high engagement from major cancer centers and patients willing to travel for treatment.

• Number of aphereses and site activations are key early metrics; updates to be provided at earnings call.

Patient identification and treatment process

• Most patients are tested for HLA and MAGE-A4 shortly before considering TECELRA; aim is to move testing earlier in diagnosis.

• Testing process takes about two weeks; total time from identification to dosing is estimated at three to four months.

• Majority of patients are commercially insured, with coverage policies in place for 70% of commercial and 77% of Medicare lives.

• No significant insurance roadblocks reported; patient group is young, active, and highly engaged in care.